Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
74 hedge funds and large institutions have $94.3M invested in Strongbridge Biopharma plc. in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 25 reducing their positions, and 7 closing their positions.
109% more call options, than puts
Call options by funds: $527K | Put options by funds: $252K
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
4% more funds holding
Funds holding: 71 → 74 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 25
1% less capital invested
Capital invested by funds: $95.3M → $94.3M (-$941K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.3M |
| 2 |
Morgan Stanley
New York
|
+$1.14M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$1.12M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$786K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$588K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$5.26M |
| 2 |
6CM
683 Capital Management
New York
|
-$3.88M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.86M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.73M |
| 5 |
Renaissance Technologies
New York
|
-$1.94M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Squarepoint
New York
| – | -$60K | -24,493 | Closed |
|
|
CS
77
Credit Suisse
Zurich,
Switzerland
| – | -$30K | -12,408 | Closed |
|
78
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$28K | -11,591 | Closed |
|
79
Fidelity Investments
Boston,
Massachusetts
| – | -$1K | -450 | Closed |
|
80
Simplex Trading
Chicago,
Illinois
| – | +$727 | +241 | New |
|
SBBP Hedge Fund Activity: Q1 2021 in Review
74 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q1 2021, worth a combined $94.3M — down 0.99% from $95.3M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new SBBP positions and 7 closed out — a net gain of 3 holders — while 25 added to existing stakes and 25 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $1.3M. The largest seller was OrbiMed, cutting an estimated $5.26M.
- 74 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q1 2021, up from 71 in Q4 2020.
- Funds reported $94.3M of Strongbridge Biopharma plc. stock for Q1 2021, down 0.99% quarter-over-quarter.
- 10 funds opened new Strongbridge Biopharma plc. positions in Q1 2021 and 7 closed out, a net change of +3 holders.
- The largest Strongbridge Biopharma plc. buyer in Q1 2021 was AIGH Capital Management, an estimated $1.3M added.
- The largest Strongbridge Biopharma plc. seller in Q1 2021 was OrbiMed, an estimated $5.26M sold.
Based on aggregated 13F filings for Q1 2021.